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Abstract  
Background and Purpose: Brain-derived neurotrophic factor (BDNF) plays important roles in 
brain plasticity and repair, and has been shown to influence stroke outcomes in animal 
models. Few clinical studies on BDNF in relation to ischemic stroke (IS) have been 
performed. The aims of the present study are to investigate whether acute circulating BDNF 
levels are: 1) altered in IS compared to controls; 2) associated with short- and long-term 
functional outcome after IS.  
 
Methods: Serum levels of BDNF were analyzed in the Sahlgrenska Academy Study on 
Ischemic Stroke. Etiologic subtypes were defined according to the TOAST criteria. 
Functional outcome was assessed using the modified Rankin Scale at 3 months, 2 years and 7 
years after stroke.  
 
Results: Acute phase BDNF levels were significantly lower in IS cases (N=491) compared to 
controls (N=513), and this was true in all main etiological subtypes. Low BDNF levels were 
associated with poor functional outcome. During long-term follow-up this association was 
independent of traditional risk factors and initial stroke severity.  
 
Conclusions: Circulating BDNF protein levels are lowered in the acute phase of stroke, and 
low levels are associated with poor long-term functional outcome. Further studies are 
necessary to confirm these associations and to determine the predictive value of BDNF in 
stroke outcomes. 
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INTRODUCTION:  
Brain-derived neurotrophic factor (BDNF) has a documented role in neurogenesis1 and 
influences functional motor recovery after an ischemic brain lesion in animal models.2 
_ENREF_3 Recently the prognostic value of circulating BDNF levels has received attention in 
some brain disorders including traumatic brain injury (TBI) and post-stroke depression (PSD). 
Acute serum BDNF levels were able to predict severity and outcome of a TBI, and patients 
with the lowest BDNF levels had the highest odds of incomplete recovery.3 Similarly, stroke 
patients that developed PSD had low admission levels of serum BDNF.4  No study has yet 
looked at BDNF proteins levels in relation to functional outcome after ischemic stroke (IS).   
BDNF may play a role also outside the central nervous system (CNS), however, the source of 
peripheral levels remains to be determined. Levels of circulating BDNF correlate with several 
vascular risk factors5-7, and low BDNF concentrations have recently been found to associate 
with an increased risk of incident stroke/TIA.8 This study aimed to determine: 1) the 
concentration of BDNF in serum of IS patients and matched controls; 2) whether acute levels 
of BDNF are associated with short-term (3 months) and/or long-term (2 and 7 years) 
functional outcome after stroke.  
METHODS:  
Additional details can be found in the Online Supplement (please see 
http://stroke.ahajournals.org) 
Study population, BDNF and outcome measurements 
Participants were from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS), the 
design of which has been reported.9 Serum samples were collected from 514 patients in the 
acute phase and from 514 matched controls. Surviving patients also underwent blood 
sampling at a 3-month follow-up. BDNF levels were measured using the BDNF Emax 
ImmunoAssay System (Promega, WI, USA). Functional outcome was assessed at 3 months, 2 
years and 7 years post-stroke by the modified Rankin Scale (mRS). For the present study, 491 
acute phase, 470 3-month, and 513 control samples were available for analysis. 
Statistical analysis 
Associations between BDNF and overall IS or TOAST subtypes were investigated using 
unconditional logistic regression analysis. Model A was adjusted for age and sex. Model B 
was additionally adjusted for hypertension, hyperlipidemia, diabetes mellitus, smoking status 
and atrial fibrillation. 
Functional outcome (good, mRS 0-2 versus poor, mRS 3-6) was evaluated by binary logistic 
regression. A threshold analysis was pre-specified, wherein patients in the lowest tertile of 
BDNF, T1, were compared to persons in T2 + T3. Model A was adjusted for age and sex. 
Model B was additionally adjusted for cardiovascular risk factors, as well as initial stroke 
severity as measured by the Scandinavian Stroke Scale (SSS). Given that there are many 
confounding factors related to death after 7 years, patients that died were excluded from the 
primary analysis. All statistical analyses were performed using SPSS for Windows version 20 
(IBM Corporation, NY, USA). The statistical significance level was 0.05 and P-values were 
two-tailed. 
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RESULTS:  
Study sample 
Baseline characteristics for SAHLSIS have been described previously.9 The distribution of 
clinical characteristics for SAHLSIS based on BDNF tertiles (T1 versus T2-T3) are presented 
in the Online Supplement (Table I, please see http://stroke.ahajournals.org). Participants in T1 
were significantly younger, had higher triglyceride levels, higher prevalence of atrial 
fibrillation, lower LDL cholesterol, lower blood pressure and lower prevalence of 
hypertension.  
Association of BDNF serum levels and stroke/subtypes 
Acute serum BDNF levels were significantly lower in IS patients compared to controls 
(geometric mean 18.3 ± 2.3 ng/ml vs 23.9 ± 1.5 ng/ml; p<0.001). In multivariable analyses, 
lower acute BDNF levels were independently associated with IS and each of the four main 
etiologic subtypes (Figure 1A). BDNF levels were lowest in patients with cardioembolic (CE) 
stroke. At 3-month follow up, BDNF levels were associated only with CE stroke (Figure 1B).  
Association of BDNF and poor functional outcome 
Acute BDNF levels were next analyzed in good (mRS 0-2) versus poor (mRS 3-6) functional 
outcome groups at 3 months, 2 years and 7 years post-stroke. The majority of patients that 
experienced poor outcome were in the lowest BDNF tertile, T1 (Figure 2A). In regression 
analyses, low BDNF levels were associated with poor functional outcome (Figure 2B). At 2 
and 7 years post-stroke this association was independent of stroke severity and traditional risk 
factors.  
 
DISCUSSION 
Here we report that circulating BDNF levels are lower in the acute phase of IS in all etiologic 
subtypes compared to healthy controls. Patients with CE stroke had the lowest levels of 
BDNF, which remained significantly lower than controls at 3-month follow-up. While 
circulating BDNF levels are positively correlated to several risk factors for metabolic 
syndrome and cardiovascular dysfunction in healthy individuals7,  low concentrations have 
been observed in patients with several risk factors associated with stroke such as metabolic 
syndrome10, type 2 diabetes mellitus5, atrial fibrillation8 and acute coronary syndromes.6 
Furthermore, low BDNF levels were recently demonstrated to be associated with an increased 
risk of incident stroke/TIA when adjusting for age, sex and traditional risk factors.8 While the 
latter studies support our findings, the mechanism of decreased serum BDNF in acute stroke 
patients requires further study.  
We also report that low acute levels of BDNF are associated with poor functional outcome up 
to 7-years after stroke. These data are in line with studies on TBI3. These findings are 
biological plausible because animal studies show that BDNF promotes neuronal remodeling 
and functional motor recovery after induction of a brain lesion.2, 11  However, it is unclear 
whether circulating BDNF values measured in this study are representative of CNS values.  
Thus an alternative explanation is that BDNF affects outcome through peripheral mechanisms 
and/or is a marker for “something” that does.  
4 
 
Irrespectively, circulating BDNF values deserve further evaluation.  
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FIGURE LEGENDS 
Figure 1: A) Odds ratios and 95% confidence intervals for ischemic stroke and subtypes per 1 
SD increase in BDNF concentration. Model A adjusted for age and sex and Model B adjusted 
for traditional risk factors. Acute levels. B) As in panel B, but at 3-month follow-up. *P<0.05, 
†P<0.01, ‡P<0.001 
 
Figure 2. A) Percentage of patients in each BDNF tertile with good or bad outcome (defined 
as mRS 0-2 = good and mRS 3-6 = bad). B) Odds ratios and 95% confidence intervals for the 
association of BDNF protein levels (T1 versus T2-3) with poor functional outcome at 3 
months, 2 years and 7 years post stroke. *P<0.05 compared with good outcome after stroke. 
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